REFERENCES

Aldridge EC Jr. 2002. Acquisition decision memorandum—management of the Chemical/Biological Defense Program. Memorandum for Secretary of the Army. Department of Defense, Washington, D.C., September 19.


DHHS (Department of Health and Human Services). 2002. Possession, use, and transfer of select agents and toxins; interim final rule. Federal Register 67(240):76885–76905.

DoD (Department of Defense). 2003. DoD medical biological defense research funding. Information provided by the Chemical and Biological Defense Program to the Institute of Medicine/National Research Council Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents. Washington, D.C.


FDA (Food and Drug Administration). 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register 67(105):37988–37998.


IOM (Institute of Medicine). 2002. Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military. Lemon SM, Thaul S, Fisseha S, O’Maonaigh H, eds. Washington, D.C.: National Academies Press.


Top FH Jr., Dingerdissen JJ, Habig WH, Quinnan GV Jr., Wells RL. 2000. DoD Acquisition of Vaccine Production: Report to the Deputy Secretary of Defense by the Independent Panel of Experts. In DoD, 2001. Report on Biological Warfare Defense Vaccine Research and Development Programs. Washington, D.C.: Department of Defense.


White House. 2003. President details Project BioShield. Washington, D.C., February 3. [Online] Available: http://www.whitehouse.gov/news/releases/2003/02/print/20030203.html [accessed February 5, 2003].



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement